Lulizumab is a humanized recombinant antibody that acts as an antagonist to the CD28 domain. This antibody selectively targets the CD28 signal, effectively inhibiting T-cell activation. In research studies, specifically using a sensitized non-human primate kidney transplantation model, Lulizumab has demonstrated the ability to modulate immune cell responses. When used in combination with Carfilzomib, it has shown potential in prolonging graft survival times, indicating its utility in transplant immunology and immune regulation studies.
Lulizumab is a humanized recombinant antibody that acts as an antagonist to the CD28 domain. This antibody selectively targets the CD28 signal, effectively inhibiting T-cell activation. In research studies, specifically using a sensitized non-human primate kidney transplantation model, Lulizumab has demonstrated the ability to modulate immune cell responses. When used in combination with Carfilzomib, it has shown potential in prolonging graft survival times, indicating its utility in transplant immunology and immune regulation studies.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
